Categories: Medical News

Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis treatment

Spread the love

Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as zygomycosis), a life-threatening invasive fungal infection caused by certain emerging molds. …read more    

AHIT

Share
Published by
AHIT

Recent Posts

South Africa steps up cancer data gathering

By: Elna Schütz [JOHANNESBURG] South Africa has begun collecting data on cancer directly from patients…

2 months ago

Kenya’s healthcare system needs immersive technologies

Kenya's healthcare system faces numerous challenges, including limited access to specialists, uneven distribution of resources…

3 months ago

Adoption of Technology to Address Africa’s Healthcare Challenges

Technological transformation has   been  advocated for a sweeping technological transformation to confront the critical healthcare…

3 months ago

AI a ‘potent remedy’ for Africa’s health challenges

By: Jackie Opara [LAGOS] Artificial Intelligence (AI) could emerge as a potent remedy for long-standing…

3 months ago

HealthTech Hub Africa receives support to fast-track health tech innovation.s across the continent.

The African Development Bank Group has entered into an agreement with the HealthTech Hub Africa…

3 months ago

Tanzania: Dawa Mkononi secures funding to enhance healthcare access

Dawa Mkononi, a B2B pharmaceutical firm based in Tanzania, focused on using innovation to improve…

4 months ago